4-((9H-carbazol-9-yl)methyl)-N-hydroxybenzamide | 1239034-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-((9H-carbazol-9-yl)methyl)-N-hydroxybenzamide
• 英文别名: 4-carbazol-9-ylmethyl-N-hydroxybenzamide；4-(carbazol-9-ylmethyl)-N-hydroxybenzamide
• CAS: 1239034-61-7
• 化学式: C₂₀H₁₆N₂O₂
• 分子量: 316.359
• InChiKey: CASUOFRPUDPLQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  54.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-[6-(4-dimethylaminophenyl)-1,2,3,4-tetrahydrocarbazol-9-yl]hexanoic acid ethyl ester 、 4-((9H-carbazol-9-yl)methyl)-N-hydroxybenzamide 生成 6-[6-(4-dimethylaminophenyl)-1,2,3,4-tetrahydrocarbazol-9-yl]hexanoic acid hydroxyamide
  参考文献：
  名称：

  HDAC Inhibitors and Therapeutic Methods of Using Same

  摘要：

  本文披露了组蛋白去乙酰化酶抑制剂（HDACIs）及其组合物。同时还披露了治疗疾病和状况的方法，其中抑制HDAC可以提供益处，例如癌症、神经退行性疾病、神经系统疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。

  公开号：

  US20130281484A1
• 作为产物：
  描述：

  methyl 4-((9H-carbazol-9-yl)methyl)benzoate 在 sodium methylate 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以41%的产率得到4-((9H-carbazol-9-yl)methyl)-N-hydroxybenzamide
  参考文献：
  名称：

  [EN] HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  [FR] INHIBITEURS DE HDAC ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT

  摘要：

  公开号：

  WO2011011186A3

文献信息

• HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME
  申请人：Kozikowski Alan

  公开号：US20120252740A1

  公开（公告）日：2012-10-04

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

  本文披露了组蛋白去乙酰化酶抑制剂（HDACIs）及其含量。同时还披露了治疗疾病和状况的方法，其中抑制HDAC能够提供益处，如癌症、神经退行性疾病、神经系统疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。
• HDAC Inhibitors and Therapeutic Methods of Using Same
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US20130281484A1

  公开（公告）日：2013-10-24

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

  本文披露了组蛋白去乙酰化酶抑制剂（HDACIs）及其组合物。同时还披露了治疗疾病和状况的方法，其中抑制HDAC可以提供益处，例如癌症、神经退行性疾病、神经系统疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。
• Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
  作者：Kyle V. Butler、Jay Kalin、Camille Brochier、Guilio Vistoli、Brett Langley、Alan P. Kozikowski

  DOI：10.1021/ja102758v

  日期：2010.8.11

  Structure-based drug design combined with homology modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isozyme compared to other inhibitors. These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies. An optimized compound from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated a-tubulin, but not histone, consistent with its HDAC6 selectivity. Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress. Importantly, when given alone at all concentrations tested, this hydroxamate-containing HDAC6-selective compound displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogues to neurodegenerative conditions.
• [EN] HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE HDAC ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV ILLINOIS

  公开号：WO2011011186A3

  公开（公告）日：2011-05-26
• HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：The Board of Trustees of the University of Illinois

  公开号：EP2456757B1

  公开（公告）日：2019-05-01